- Celanese Corp (NYSE:CE) has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
- CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
- Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
- “The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe,” commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
- Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.
5 Analysts Dissect Lyft Strategy: October ‘Sustained Strength’ Bodes Well For Q4
Shares of Lyft Inc (NASDAQ: LYFT) continued to decline in early trading on Thursday, after tanking in the previous trading session on the company’s third-quarter earnings.
